Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to ...

Alongside the leadership change, Kenvue revealed that its Board had previously initiated a comprehensive review of strategic alternatives and established a Strategic Review Committee. The review will ...

Band-Aid and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what ...

Kenvue names interim CEO, begins strategic review to simplify operations and considers divesting smaller beauty brands amid ...

The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

Kenvue (NYSE:KVUE) recently experienced a 2% price increase over the past week, a move that coincides with notable executive changes. The replacement of the CEO with Kirk L. Perry as interim CEO, ...

The Company believes these measures help improve investors’ ability to understand the Company’s operating performance ... (conversion of stock-based awards, stock-based awards granted to individuals ...

The stock has a high yield at 3.9%, which is significantly higher than well-known Dividend Kings like Coca-Cola or Procter & ...

Kenvue stock reversed lower Monday after the company — known for brands like Tylenol — announced a new CEO and strategic ...